Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
B7-H1 Antigen
/ genetics
Biomarkers, Tumor
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ genetics
Endoscopic Ultrasound-Guided Fine Needle Aspiration
ErbB Receptors
/ genetics
Humans
Lung
/ metabolism
Lung Neoplasms
/ pathology
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
/ genetics
Proto-Oncogene Proteins B-raf
/ genetics
Reactive Oxygen Species
Retrospective Studies
Non-small cell lung carcinoma
endobronchial ultrasound
lung cancer biomarker
molecular analysis
targeted therapy
Journal
Scottish medical journal
ISSN: 0036-9330
Titre abrégé: Scott Med J
Pays: Scotland
ID NLM: 2983335R
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
pubmed:
12
2
2022
medline:
27
4
2022
entrez:
11
2
2022
Statut:
ppublish
Résumé
Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject. The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers. We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020. A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing. EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.
Sections du résumé
BACKGROUND
BACKGROUND
Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.
AIM
OBJECTIVE
The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.
METHODS
METHODS
We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.
RESULTS
RESULTS
A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.
CONCLUSION
CONCLUSIONS
EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.
Identifiants
pubmed: 35147461
doi: 10.1177/00369330221078995
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Proto-Oncogene Proteins
0
Reactive Oxygen Species
0
ErbB Receptors
EC 2.7.10.1
Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM